Neural ID, a provider of collaborative biosignal analytics platform spanning the pharmaceutical lifecycle, has joined with IDBS. The collaborative offering combines BioBook, IDBS’ electronic laboratory notebook for life sciences and Neural ID’s product IWS, which provides users with automated data analysis and data reporting.
BioBook users will achieve full traceability and drill down capacity of the study lifecycle. This includes summary reports of study design, analyzed data and processed instrumentation biosignals. The summary data reported into BioBook from IWS will be fully searchable. Users of IWS will be able to generate deep analytic value across cardio safety assessments from discovery through clinical applications and support GxP regulated environments.
“Researchers are keen to reduce study cycle times and accelerate decision making around the safety and efficacy of new products. We recognize the need for a consistent and reproducible way to automate waveform analysis throughout the drug discovery and development lifecycle,” said Scott Weiss, director, Product Strategy, IDBS. “The integration will eliminate manual data import, reducing transcription errors. It also provides improved user productivity with automated write-up and reporting.”